International Staging System for Multiple Myeloma
Top Cited Papers
- 20 May 2005
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (15), 3412-3420
- https://doi.org/10.1200/jco.2005.04.242
Abstract
There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification. Clinical and laboratory data were gathered on 10,750 previously untreated symptomatic myeloma patients from 17 institutions, including sites in North America, Europe, and Asia. Potential prognostic factors were evaluated by univariate and multivariate techniques. Three modeling approaches were then explored to develop a staging system including two nontree and one tree survival assessment methodologies. Serum beta2-microglobulin (Sβ2M), serum albumin, platelet count, serum creatinine, and age emerged as powerful predictors of survival and were then used in the tree analysis approach. A combination of Sβ2M and serum albumin provided the simplest, most powerful and reproducible three-stage classification. This new International Staging System (ISS) was validated in the remaining patients and consists of the following stages: stage I, Sβ2M less than 3.5 mg/L plus serum albumin ≥ 3.5 g/dL (median survival, 62 months); stage II, neither stage I nor III (median survival, 44 months); and stage III, Sβ2M ≥ 5.5 mg/L (median survival, 29 months). The ISS system was further validated by demonstrating effectiveness in patients in North America, Europe, and Asia; in patients less than and ≥ 65 years of age; in patients with standard therapy or autotransplantation; and in comparison with the Durie/Salmon staging system. The new ISS is simple, based on easy to use variables (Sβ2M and serum albumin), and recommended for early adoption and widespread use.Keywords
This publication has 38 references indexed in Scilit:
- Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma FoundationThe Hematology Journal, 2003
- Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factorsBritish Journal of Haematology, 1999
- Survival Trees by Goodness of SplitJournal of the American Statistical Association, 1993
- Graphical Methods for Censored DataJournal of the American Statistical Association, 1991
- The Role of Cis-Acting Promoter Elements in Tissue-Specific Albumin Gene ExpressionScience, 1989
- Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.British Journal of Haematology, 1983
- β2-MICROGLOBULIN, A TUMOUR MARKER OF LYMPHOPROLIFERATIVE DISORDERSThe Lancet, 1978
- PART I. ANALYSIS OF PRESENTING FEATURES OF PROGNOSTIC IMPORTANCEBritish Journal of Haematology, 1973
- Factors influencing the prognosis in myelomatosisHeart, 1971
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958